Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108284 | 0.83 | MAPT (0.35) | CYP1A2CYP2C19ALDH1A1CA2 | |
| SCHEMBL9291606 | 0.79 | CYP1A2 (0.36) | CYP1A2CYP2C19ALDH1A1LMNAHSD17B10 | |
| SCHEMBL12824764 | 0.78 | CYP1A2 (0.35) | CYP1A2CYP2C19ALDH1A1LMNAHSD17B10 | |
| SCHEMBL11982518 | 0.73 | KMT2A (0.50) | ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL9291884 | 0.66 | CYP1A2 (0.33) | CYP1A2CYP2C19ALDH1A1KMT2AMEN1 | |
| SCHEMBL12888807 | 0.61 | ALDH1A1 (0.41) | CYP1A2CYP2C19ALDH1A1LMNAHSD17B10 | |
| SCHEMBL2111888 | 0.60 | ALDH1A1 (0.44) | CYP1A2CYP2C19ALDH1A1LMNAHSD17B10 | |
| SCHEMBL13034117 | 0.59 | ALDH1A1 (0.48) | CYP1A2CYP2C19ALDH1A1LMNAHSD17B10 | |
| SCHEMBL8897496 | 0.58 | HSD17B10 (0.51) | CYP1A2CYP2C19ALDH1A1LMNAHSD17B10 | |
| SCHEMBL9685052 | 0.57 | ALDH1A1 (0.50) | CYP1A2CYP2C19ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | CYP1A2 1095/4885CYP2C19 570/4885ALDH1A1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.